Academic Journal
Physiologic Improvement in Respiratory Acidosis Using Extracorporeal Co 2 Removal With Hemolung Respiratory Assist System in the Management of Severe Respiratory Failure From Coronavirus Disease 2019
| العنوان: | Physiologic Improvement in Respiratory Acidosis Using Extracorporeal Co 2 Removal With Hemolung Respiratory Assist System in the Management of Severe Respiratory Failure From Coronavirus Disease 2019 |
|---|---|
| المؤلفون: | Akkanti, Bindu, Jagpal, Sugeet, Darwish, Ribal, Saavedra Romero, Ramiro, Scott, L. Keith, Dinh, Kha, Hussain, Sabiha, Radbel, Jared, Saad, Mohamed A., Enfield, Kyle B., Conrad, Steven A. |
| المصدر: | Critical Care Explorations ; volume 3, issue 3, page e0372 ; ISSN 2639-8028 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2021 |
| الوصف: | Objectives: About 15% of hospitalized coronavirus disease 2019 patients require ICU admission, and most (80%) of these require invasive mechanical ventilation. Lung-protective ventilation in coronavirus disease 2019 acute respiratory failure may result in severe respiratory acidosis without significant hypoxemia. Low-flow extracorporeal C o 2 removal can facilitate lung-protective ventilation and avoid the adverse effects of severe respiratory acidosis. The objective was to evaluate the efficacy of extracorporeal C o 2 removal using the Hemolung Respiratory Assist System in correcting severe respiratory acidosis in mechanically ventilated coronavirus disease 2019 patients with severe acute respiratory failure. Design: Retrospective cohort analysis of patients with coronavirus disease 2019 mechanically ventilated with severe hypercapnia and respiratory acidosis and treated with low-flow extracorporeal C o 2 removal. Setting: Eight tertiary ICUs in the United States. Patients: Adult patients supported with the Hemolung Respiratory Assist System from March 1, to September 30, 2020. Interventions: Extracorporeal C o 2 removal with Hemolung Respiratory Assist System under a Food and Drug Administration emergency use authorization for coronavirus disease 2019. Measurements and Main Results: The primary outcome was improvement in pH and Pa co 2 from baseline. Secondary outcomes included survival to decannulation, mortality, time on ventilator, and adverse events. Thirty-one patients were treated with Hemolung Respiratory Assist System with significant improvement in pH and P co 2 in this cohort. Two patients experienced complications that prevented treatment. Of the 29 treated patients, 58% survived to 48 hours post treatment and 38% to hospital discharge. No difference in age or comorbidities were noted between survivors and nonsurvivors. There was significant improvement in pH (7.24 ± 0.12 to 7.35 ± 0.07; p < 0.0001) and Pa co 2 (79 ± 23 to 58 ± 14; p < 0.0001) from baseline to 24 hours. Conclusions: In this ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1097/cce.0000000000000372 |
| DOI: | 10.1097/CCE.0000000000000372 |
| الاتاحة: | http://dx.doi.org/10.1097/cce.0000000000000372 https://journals.lww.com/10.1097/CCE.0000000000000372 |
| Rights: | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.64559180 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/cce.0000000000000372 |
|---|